5 Stocks To Buy That Pay A 5% Dividend Yield

BP plc (LON:BP), Centrica PLC (LON:CNA), GlaxoSmithKline plc (LON:GSK), Royal Dutch Shell Plc (LON:RDSB) and Vodafone Group Plc (LON:VOD) all yield more than 10 times today’s base rate

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

I still can’t get over the fact that solid FTSE 100 players like BP (LSE: BP), Centrica (LSE: CNA), GlaxoSmithKline (LSE: GSK), Royal Dutch Shell (LSE: RDSB) and Vodafone (LSE: VOD) all now yield 5% or more… while cash gives savers a near-zero return!

Too many savers fail to realise how much income they could generate by taking a bit of extra risk with their money, plus the scope for capital growth as well. 

So which of these five stocks are your best income options?

BP

The plummeting oil price has hit BP, whose shares are down 12% in just three months. But that’s good news for income seekers, because a lower share price means a higher yield. Today, you get a juicy 5.3%.

This is riskier than leaving your money in the bank, with Deepwater Horizon legal wrangles dragging on interminably, and BP’s 20% stake in Kremlin-controlled oil enterprise Rosneft succumbing to sanctions.

If you can accept these risks, today’s valuation of just 5.6 times earnings may be a good entry point for long-term investors.

Centrica

British Gas owner Centrica offers an even more generous income of 5.8% a year. Again, a falling share price has helped, with the stock down 17% in the last year, over fears that Labour leader Ed Miliband will punish utility companies if he wins next May’s election.

But these fears are priced in, with Centrica trading at 11 times earnings, and its electric income will keep savers warm this winter.

GlaxoSmithKline

Pharmaceutical giant GlaxoSmithKline is yet another FTSE 100 income hero to stumble, its share price down 15% in six months on the Chinese bribery scandal and falling sales.

Today’s price of 12.6 times earnings looks tempting, especially since it secures you an income of 5.5% a year. And there is scope for capital growth, with profits set to flow from its R&D pipeline.

Royal Dutch Shell

Anglo-Dutch oil major Royal Dutch Shell has had a less turbulent year than BP, yet its share price is still down 9% in three months, largely on the oil price slide.

Shell is more expensive than BP, at 14 times earnings, and its dividend is slightly lower at 5%. But it pumps out cash, posting a $6.1bn profit in the second quarter alone, and looks a lot less risky than its rival right now.

Vodafone

Telecommunications giant Vodafone is another UK blue-chip going cheap, down more than 9% in six months. This really is a great time to go shopping for stocks.

Vodafone is throwing off enough cash to splurge $19 billion on its Project Spring revamp, but still has enough left over to pay you a generous income of 5.52% a year.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »